Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
Andrei Floroiu
|
| gptkbp:country |
gptkb:United_States
|
| gptkbp:developedVaccineFor |
gptkb:COVID-19
gptkb:RSV gptkb:norovirus influenza |
| gptkbp:focusesOn |
infectious diseases
oral vaccines |
| gptkbp:founded |
2004
|
| gptkbp:founder |
Sean Tucker
|
| gptkbp:headquartersLocation |
gptkb:South_San_Francisco,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Vaxart
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:notableEvent |
COVID-19 vaccine candidate entered clinical trials in 2020
|
| gptkbp:platform |
proprietary oral vaccine delivery
|
| gptkbp:productType |
oral tablet vaccines
|
| gptkbp:publiclyTraded |
true
|
| gptkbp:stockSymbol |
VXRT
|
| gptkbp:tradedOn |
NASDAQ: VXRT
|
| gptkbp:website |
https://www.vaxart.com/
|
| gptkbp:bfsParent |
gptkb:South_San_Francisco,_California,_USA
|
| gptkbp:bfsLayer |
7
|